#biotechnology — Public Fediverse posts

Korea University Study Uncovers How mRNA Vaccination May Broaden Flu Antibody Responses

New study finds that mRNA vaccination sustained influenza-specific germinal-center activity for up to six months in some participants…
#EuropeSays #Korea #KR #Biotechnology #ClinicalTrials&MedicalDiscoveries #HealthCare&Hospitals #InfectionControl #KoreaUniversityCollegeofMedicine #MedicalEquipment #MedicalPharmaceuticals #Pharmaceuticals #PollsandResearch #publicsafety #Surveys
https://www.europesays.com/korea/151333/

https://www.europesays.com/dk/164360/ Novartis, Novo Nordisk drug flops will likely ‘pop a hole in the balloon’ of field #Biotechnology #cardiology #DrugDevelopment #Novartis #NovoNordisk #Pharmaceuticals #STAT+

https://www.europesays.com/ch/129378/ Novartis, Novo Nordisk drug flops will likely ‘pop a hole in the balloon’ of field #biotechnology #cardiology #DrugDevelopment #Novartis #NovoNordisk #Pharmaceuticals #STAT+

🔬 Is it time to challenge the single-target mindset in exosome research?

🔗 Engineering Magnetic Beads for Affinity Enrichment of Exosomes. Computational and Structural Biotechnology Journal (CSBJ). DOI: https://doi.org/10.34133/csbj.0170

📚 CSBJ - A Science Partner Journal: https://spj.science.org/journal/csbj

#Exosomes #ExtracellularVesicles #Biotechnology #MagneticBeads #Bioengineering #Diagnostics #Nanobiotechnology #Biomarkers #DrugDelivery #PrecisionMedicine

📢 Call for Papers: Computational and Experimental Advances in Carbohydrate-Active Enzymes

⏳ Submission Deadline: 31 May 2027

🔗 Submit your work: https://spj.science.org/journal/csbj/si/carbohydrate-active-enzymes

#CallForPapers #CAZymes #CarbohydrateActiveEnzymes #EnzymeEngineering #ComputationalBiology #StructuralBiology #Bioinformatics #ArtificialIntelligence #MachineLearning #ProteinEngineering #SyntheticBiology #Metagenomics #Biotechnology #BiomassValorization #CircularBioeconomy

Toward An Inclusive Bioeconomy Framework For Global Mountains
--
https://doi.org/10.48130/cas-0026-0003 <-- shared paper
--
https://adaptationataltitude.org/knowledge-base/adaptation-in-mountains/mountain-ecosystems-for-a-resilient-future-policy-pathways-under-the-cbd-and-unfccc/ <-- shared technical article
--
https://blog.icimod.org/hi-reap/from-biodiversity-to-livelihoods-bhutans-bioeconomy-pathways/ <-- shared technical article, “From biodiversity to livelihoods: Bhutan’s bioeconomy pathways”
--
“Global mountain regions have great biological, cultural, and spiritual value for people around the world, but progress in efforts to conserve montane resources has been slow. International researchers are now acting to construct a bioeconomy framework for global mountains that includes biodiversity, cultural protection, and restoration, circular economy principles, biotechnology innovation, digital integration, sustainable fair trade, and social equity and justice. Plans in five mountain regions are reviewed for initial actions to implement this framework…”
#MountainBioeconomy #mountain #bioeconomy #economy #CircularEconomy #Biodiversity #conservation #biocultural #protection #diversity #biology #culture #circulareconomy #biotechnology #digitalintegration #sustainable #fairtrade #socialequity #socialjustice #montane #bioeconomy #global #success #metrics #montanebioeconomy #community #connection #mountain #framework #planning #policy #framing #agriculture #sustainable #foodsecurity #farmers #circularagriculture

Colossal Biosciences Is Making Jurassic Park Look Like a Pitch Deck

Dear Cherubs, Dallas has apparently decided extinction is just a product category. Colossal Biosciences is now a billionaire-level biotech spectacle, with the company saying its latest Series C brought total funding to $615 million and ABC News reporting a roster of celebrity backers that includes Tom Brady, Tiger Woods, Paris Hilton and Peter Jackson. Dallas Innovates also reported that the CIA’s venture arm, In-Q-Tel, invested in Colossal back in 2022.

The result is a company that sounds like it was brainstormed by a film studio, a venture fund and a very committed science teacher. Colossal says it is working on de-extinction projects tied to the woolly mammoth, dodo, thylacine and dire wolf, using gene editing, synthetic biology and related conservation tools. So no, this is not literally Jurassic Park; it is more like Jurassic Park after legal review and a lot of grant money.

THE TEA, BUT WITH MICROPIPETTES

In April, Reuters reported that Colossal announced three genetically engineered wolf pups and called them the world’s first successfully “de-extincted” animals, while outside experts were more cautious and described them as genetically modified gray wolves with added dire-wolf traits. ABC News said Colossal edited gray wolf cells at multiple sites and noted the two species are about 99.5% genetically identical, which is a very impressive number and also a reminder that biology is rude and complicated.

That is the key detail the movie version never pauses for: the company is not dusting off a frozen dinosaur and pressing play. It is using ancient DNA, gene editing and surrogate biology to create something that resembles an extinct species closely enough to trigger headlines, debates and a healthy amount of side-eye. The label “de-extincted” is doing a lot of heavy lifting here.

WHY THE MONEY FLOWS

The money makes more sense when you look at the technology stack. Dallas Innovates reported that In-Q-Tel said its interest in Colossal was “less about the mammoths and more about the capability,” while Colossal’s own materials say the work could scale CRISPR, synthetic biology, artificial wombs and genomic preservation platforms. In other words, the extinct-animal angle is the headline; the platform is the business.

Colossal has also built a pop-culture-friendly halo around the science. Its advisory board page lists Tom Brady and George R.R. Martin among its cultural advisors, which is exactly the kind of sentence that makes the internet stop scrolling for a second. That is the trick here: make de-extinction feel part science, part blockbuster, part meme, and suddenly the cap table looks almost inevitable.

The hot take is simple: this is not a cartoonish clone factory, and it is not pure hype either. It is a very expensive attempt to push gene editing, cloning-adjacent methods and reproductive tech into territory that could one day matter for conservation as much as spectacle. The dinosaurs are still fiction, but the lab bills are extremely real.

Sources list
ABC News — https://abcnews.go.com/US/dire-wolf-revived-biotech-companys-de-extinction-process/story?id=120558562
Reuters — https://www.reuters.com/science/us-company-resurrects-extinct-dire-wolf-or-some-version-it-2025-04-08/
Dallas Innovates — https://dallasinnovates.com/mammoth-interest-the-cia-invests-in-dallas-based-colossal-biosciences/
Colossal Biosciences — https://colossal.com/colossal-secures-200m-to-accelerate-de-extinction-and-genomic-innovation/
Colossal Biosciences — https://colossal.com/advisors/
Wikimedia Commons (Laboratory.jpg) — https://commons.wikimedia.org/wiki/File:Laboratory.jpg

Kimchi probiotic helps remove nanoplastics from the intestine.

A bacterium isolated from kimchi can bind to nanoplastics in the intestine and increase their elimination through feces, a Korean study suggests.

Read more: https://omniletters.com/en/kimchi-probiotic-nanoplastics-excretion-intestine/

#Science #Health #Probiotics #Kimchi #Microplastics #Nanoplastics #GutHealth #Nutrition #Research #Biotechnology

Will AI replace scientists or boost them? Future favors adapters!
Learn AI + bioinformatics with BioResire.
Join students: https://whatsapp.com/channel/0029Vb5u2Tp77qVTb1D7bu3r

#AIinScience #BioResire #Bioinformatics #AIScientists #LifeSciences #BiotechFuture #ResearchAI #IndiaBiotech #Biotechnology #AICollaboration #BioResireStudents #FutureScientists #MachineLearningBiology #STEMFuture #BioinfoAI #CareerBoost #WhatsAppCommunity #ScienceTech #AIvsScientists #LifeScienceAI

3 gene editing technologies transforming biology 🧬

CRISPR-Cas9: targeted cutting → knockout or insertion

Base editing: single-nucleotide changes, no double-strand breaks  

Prime editing: insert, delete, or replace sequences with precision

For aging research: correcting genetic changes, enhancing repair, engineering resilience

#CRISPR #GeneEditing #Biotechnology #AgingResearch #PrecisionMedicine

Degree alone not enough for biotech future? Skills rule now!
Bioinformatics & AI demand surges—upgrade with BioResire.
Join WhatsApp community: https://whatsapp.com/channel/0029Vb5u2Tp77qVTb1D7bu3r
WhatsApp: 6301352398 [email protected] #DegreeVsSkills #BioResire #BiotechSkills #Bioinformatics #FutureJobs #LifeSciences #BiotechCareers #IndiaBiotech #SkillGap #Biotechnology #ResearchSkills #AIinBiology #CareerGrowth #STEMSkills #JobReady #BioinformaticsTraining #PharmaCareers #IndustrySkills #BioResireTraining #LifeScienceJob

🚨 Fake biotech placement guarantees? Don't fall for it!
High fees, no jobs—BioResire builds real skills instead.
Join WhatsApp community: https://whatsapp.com/channel/0029Vb5u2Tp77qVTb1D7bu3r

#FakePlacements #BiotechScams #BiotechJobs #PlacementGuarantee #BioResire #BiotechTraining #IndiaBiotech #LifeSciences #BiotechCareers #JobScams #Biotechnology #ResearchSkills #StudentAlert #BiotechIndia #PharmaJobs #SkillBasedLearning #BiotechFraud #CareerAdvice #WhatsAppCommunity #LifeScienceJobs

Culture Media Quick Lab Guide from BioResire!
Basal, Selective (MacConkey), Differential (MacConkey), Enrichment (Selenite F) for bacteria growth.
Internships: [email protected] #CultureMedia #Microbiology #BloodAgar #ChocolateAgar #MacConkeyAgar #SelectiveMedia #DifferentialMedia #EnrichmentMedia #Biotechnology #BioResire #LabMedia #Microbiologist #BacteriaCulture #LifeSciences #Biotech #MicrobiologyLab #LabTechniques #Science #Biology #Internship

🔬 Learn Endospore Staining using the Schaeffer–Fulton method and master essential microbiology lab techniques for research, diagnostics, and biotechnology careers.
#Microbiology #EndosporeStaining #LabTechniques #Biotechnology #LifeSciences #MicrobiologyLab #BiotechStudents #ResearchSkills #LaboratoryScience #BioResire

🌱 GM crops use biotechnology 🧬 to improve yield, nutrition, and pest resistance, supporting sustainable agriculture and global food security 🌍.
#GMCrops #Biotechnology #GeneticEngineering #AgriculturalBiotech #FoodSecurity #BtCotton #GoldenRice #LifeScienceStudents #BiologyConcepts #BioResire

🧫 Gram staining simplifies bacterial identification 🔬, revealing Gram-positive and Gram-negative differences—an essential microbiology lab technique students must master 📚.

#GramStaining #MicrobiologyLab #LifeScienceStudents #Bacteriology #MedicalMicrobiology #LabTechniques #MicrobiologyPractical #Biotechnology #BioResire #ScienceEducation

Abbott plans marketing push for glucose monitors beyond diabetes  — Morphic kept it simple in M&A maneuvers, staying focused on Lilly to reel in $3.2B buyout— FDA launches innovation hub to spur rare disease R&D —http://bit.ly/w28kSd #cgms #glucosemonitoring #abbottlabs #elililly #innovation #fda #rarediseases #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

5 neuro data readouts to watch in the second half of 2024 — GSK moves to new HQ in return to central London — AbbVie led the way in paying doctors to pitch its drugs last year —http://bit.ly/w28kSd #clinicaltrials #neurology #gsk #london #abbvie #physicians #physicianpayments #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster—GLP-1s may cut risk of 10 obesity-related cancers in diabetics —Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births —http://bit.ly/w28kSd #mergersandacquistions #elililly #ibd #takeda #glp1 #novonordisk #diabetes #cancer #pfizer #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer—FDA panel to review psychedelic drug MDMA for first time — Abbott’s OTC glucose monitor ‘will grow the market’—http://bit.ly/w28kSd #asco2024 #oncology #cancer #bristolmyerssquibb #livercancer #mdma #fda #abbottlabs #cgm #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck’s potential $3B EyeBio acquisition puts drugmaker back in ophthalmology—J&J's depression treatment succeeds in late-stage study — AstraZeneca throws its hat into the oral PCSK9 ring--http://bit.ly/w28kSd #merck #mergersandacquistions #clinicaltrials #ophthalmology #depression #jnj #astrazeneca #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Takeda joins hot molecular glue market with $1.2B deal—AstraZeneca pays $19M to Harbour BioMed's Nona for preclinical cancer antibodies —Pfizer expands cost cuts with new $1.5B target --http://bit.ly/w28kSd #takeda #molecularglue #astrazeneca #pfizer #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B—Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset —9 top biopharma CEO-to-employee pay gaps --http://bit.ly/w28kSd #biogen #mergersandacquisitions #boehringeringelheim #cardiovasculardisease #pharmaceos #executivecompensation #paygap #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --http://bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Novo Nordisk owner buys majority stake in Austrian life science tools company—As sales of weight loss drugs skyrocket, the insulin market falters —Eisai starts rolling submission for injectable version of Alzheimer's drug with FDA --http://bit.ly/w28kSd #novonordisk #mergersandacquisitions #insulin #diabetes #alzheimers #eisai #biogen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

BIOSECURE Act gets update, gives US drugmakers until 2032 to sever ties with Chinese biotechs—Sanofi pays $80M to add Roche-rivaling Fulcrum drug to phase 3 rare disease pipeline —Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot --http://bit.ly/w28kSd #biosecureact #china #legislation #Sanofi #takeda #alzheimers #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Keytruda strikes out again in endometrial cancer with phase III flop—Novo inks $600M deal with Metaphore to develop next-gen obesity drugs —Takeda Pharma to restructure after annual profit slump --http://bit.ly/w28kSd #merck #keytruda #endometrialcancer #clinicaltrials #novonordisk #obesity #drugdevelopment #takeda #restructuring #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows—Biogen cost cuts drive profit beat, Alzheimer's drug sales jump —Enter Xaira, with $1bn for its AI in drug discovery platform--http://bit.ly/w28kSd #medicare #wegovy #novonordisk #biogen #earnings #drugdiscovery #ai #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts—Takeda pushes one narcolepsy program into phase III, discontinues another — Moderna shares slide as longer-term data shows quick fall in RSV vaccine efficacy--http://bit.ly/w28kSd #senate #ceos #drugpricing #berniesanders #takeda #clinicaltrials #narcolepsy #moderna #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news http://bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Digital Biomarkers Shown to Highlight Parkinson’s Disease

Early findings indicate calculations from MRI scans of white matter lesions in the brain can distinguish between Parkinson's disease and other neurological conditions.

https://sciencebusiness.technewslit.com/?p=44970

#News #Business #Science #Biotechnology #Engineering #Biomarkers #ParkinsonsDisease #Neuroscience #Neurology #WhiteMatter #Brain #MRI #DigitalHealth #Diagnostics #France #Europe

Biotech Gains $53.7M Infectious Disease Test Award

A maker of #diagnostics for #infectious diseases is receiving a $53.7 million #contract to develop and validate reliable #home molecular #tests for Covid-19 and #flu infections.

https://sciencebusiness.technewslit.com/?p=44709

#News #Science #Business #Covid19 #SARSCoV2 #Influenza #MedicalDevice #PointOfCare #Biotechnology #MachineLearning #BARDA #FDA

Biotech, Academic Lab Partner on Microbiome-Safe Products

A #biotechnology company creating products for #gut #health and a #university #immunology lab are evaluating #cleaning products for potential damage to human protective tissues.

https://sciencebusiness.technewslit.com/?p=44345

#News #Science #Business #Chemistry #Microbiome #GutMicrobes #Detergents #Alcohol #RinseAgents #Microfluidics #Collaboration

Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth - Health and life science specialist investment firm Foresite Capital has raised a new fund, its fifth... - http://feedproxy.google.com/~r/Techcrunch/~3/XbNrLTgG8gE/ #corporatefinance #entrepreneurship #foresitecapital #machinelearning #fundings&exits #startupcompany #venturecapital #biotechnology #privateequity #jimtananbaum #innovation #investment #alphabet #articles #vikbajaj #biotech

Bit Bio’s “enter button for the keyboard to the software of life” nabs the company $41.5 million - Bit Bio, the new startup which pitches itself as the “enter button for the keyboard to the software ... more: http://feedproxy.google.com/~r/Techcrunch/~3/o1XXsLdwhSs/ #archventurepartners #cambridgeuniversity #blueyardcapital #drugdevelopment #foresitecapital #operatingsystem #biotechnology #drugdiscovery #unitedkingdom #lifesciences #stemcells #director #meatable #biology #disease